---
title: "Pan Drugs Ltd (531440) — Share Price, Financials & Analysis"
symbol: "531440"
company: "Pan Drugs Ltd"
canonical: "https://tapetide.com/stocks/531440"
bse_code: "531440"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T18:58:26.191Z"
---

# Pan Drugs Ltd (531440)

Canonical page: https://tapetide.com/stocks/531440

## Company

- **BSE Code:** 531440
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** pandrugsltd.com

## Latest Price

## Key Insights

### Weaknesses

- Company has low interest coverage ratio.

## Growth Rates

| Metric | 1Y |
| --- | --- |
| revenue growth | -26% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 5.39 | 9.67 | 8.89 | 7.44 | 8.41 | 12.49 | 5.52 | 8.92 | 6.45 | 4.15 | 5.58 |
| Expenses | 4.26 | 9.6 | 8.48 | 7.84 | 8.3 | 12.28 | 4.86 | 9.14 | 6.2 | 4.13 | 5.53 |
| Operating Profit | 1.13 | 0.07 | 0.41 | -0.4 | 0.11 | 0.21 | 0.66 | -0.22 | 0.25 | 0.02 | 0.05 |
| OPM % | 20.96 | 0.72 | 4.61 | -5.38 | 1.31 | 1.68 | 11.96 | -2.47 | 3.88 | 0.48 | 0.9 |
| Other Income | -0.02 | 0.02 | 0.2 | 0.09 | 0.01 | 0.02 | 0.05 | 0.33 | 0.04 | 0.05 | 0.07 |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0.01 | 0.01 |
| Depreciation | 0.14 | 0.15 | 0.16 | 0.15 | 0.15 | 0.15 | 0.2 | 0.71 | 0.19 | 0.19 | 0.19 |
| Profit before tax | 0.96 | -0.07 | 0.44 | -0.47 | -0.04 | 0.07 | 0.5 | -0.61 | 0.1 | -0.13 | -0.08 |
| Tax % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0.96 | -0.06 | 0.44 | -0.47 | -0.05 | 0.07 | 0.5 | -0.61 | 0.1 | -0.13 | -0.08 |
| EPS in Rs | 3.05 | -0.19 | 1.4 | -1.5 | -0.16 | 0.22 | 1.59 | -1.94 | 0.32 | -0.41 | -0.25 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | TTM |
| --- | --- |
| Sales | 25.1 |
| Expenses | 25 |
| Operating Profit | 0.1 |
| OPM % | 0.4 |
| Other Income | 0.49 |
| Interest | 0.03 |
| Depreciation | 1.28 |
| Profit before tax | -0.72 |
| Net Profit | -0.72 |
| EPS in Rs | -2.28 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 |
| Reserves | 35 | 33 | 40 | 56 | 74 | 93 | 108 | 124 | 137 | 139 |
| Borrowings | 2 | 5 | 5 | 3 | 2 | 1 | 0 | 0 | 0 | 0 |
| Other Liabilities | 15 | 12 | 8 | 10 | 21 | 18 | 20 | 23 | 33 | 32 |
| Total Liabilities | 56 | 55 | 58 | 74 | 102 | 117 | 133 | 152 | 174 | 177 |
| Fixed Assets | 7 | 3 | 3 | 3 | 3 | 3 | 4 | 18 | 19 | 26 |
| CWIP | 1 | 2 | 0 | 0 | 6 | 12 | 19 | 5 | 4 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 48 | 50 | 55 | 72 | 93 | 101 | 109 | 129 | 151 | 151 |
| Total Assets | 56 | 55 | 58 | 74 | 102 | 117 | 133 | 152 | 174 | 177 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -14 | 12 | -13 | 1 | 6 | 11 | 24 | -4 | 28 | 2 |
| Cash from Investing Activity | 3 | -4 | 4 | -2 | 0 | 0 | -12 | -7 | -23 | 10 |
| Cash from Financing Activity | 4 | -2 | 3 | -2 | -1 | -4 | -2 | 1 | -1 | -5 |
| Net Cash Flow | -7 | 6 | -6 | -2 | 4 | 8 | 9 | -10 | 4 | 7 |

### Ratios

| Item | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 222 | 105 | 173 | 187 | 182 | 269 | 194 | 216 | 143 | 164 |
| Cash Conversion Cycle | 222 | 105 | 173 | 187 | 182 | 269 | 194 | 216 | 143 | 164 |
| Working Capital Days | 157 | 42 | 191 | 188 | 212 | 210 | 172 | 221 | 142 | 148 |
| ROCE % | -15 | -6 | 9 | 23 | 39 | 31 | 28 | 16 | 17 | 15 |

## Shareholding Pattern

### annual

| Category | Mar 2017 | Dec 2017 |
| --- | --- | --- |
| Promoters | 39.36% | 39.36% |
| Public | 60.64% | 60.64% |
| No. of Shareholders | 2295 | 2295 |

### Quarterly

| Category | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 34.43% | 34.43% | 34.43% | 39.36% | 39.36% | 39.36% | 39.36% |
| Public | 65.57% | 65.57% | 65.57% | 60.64% | 60.64% | 60.64% | 60.64% |
| No. of Shareholders | 2386 | 2386 | 2386 | 2295 | 2295 | 2295 | 2295 |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 30 Jan - Regulation 29(2) disclosure received from promoter MD C.K. Shastri on Jan 30, 2026; no transaction details. | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 30 Jan - Regulation 29(2) disclosure received from promoter MD C.K. Shastri on Jan 30, 2026; no transaction details.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/70298E71_21E0_4F18_A153_3CB790F40E76_173435.pdf) |
| 30 Jan - Promoter Tikam Sujan sold 1,193,391 shares (5.05%) on Jan 29, 2026; holding now 136,293 (0.57%). | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 30 Jan - Promoter Tikam Sujan sold 1,193,391 shares (5.05%) on Jan 29, 2026; holding now 136,293 (0.57%).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3DE30354_B637_4BBD_AEF0_D6DB29426202_172657.pdf) |
| 15 Jan - Pease find enclosed the Newspaper publication for the Financial Results for the period ended December 31, 2025 | [Announcement under Regulation 30 (LODR)-Newspaper Publication 15 Jan - Pease find enclosed the Newspaper publication for the Financial Results for the period ended December 31, 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e99569e7-61e0-43fa-9dda-0d3ae5b2ea93.pdf) |
| 13 Jan - Q3 FY26 unaudited: Total income 3,541.44; EBITDA 551.47; Net profit 317.07; three new clients; SOC2, CERT-In. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 13 Jan - Q3 FY26 unaudited: Total income 3,541.44; EBITDA 551.47; Net profit 317.07; three new clients; SOC2, CERT-In.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/76b85e38-2503-4c7b-a6e4-002fe8eb4f7d.pdf) |
| — | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 31 Jan](https://www.bseindia.com/xml-data/corpfiling/AttachHis/19E47393_FC55_49E9_9865_61A3B5DEF790_103007.pdf) |
| — | [PCS Certificate For Transfer/Transmission For The Quater Ended September,2017 14 Oct 2017](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2eee51be-04d5-42e1-928b-e2f035ea83b4.pdf) |
| — | [Statement Of Investor Complaints For The Quater Ended June,2017 14 Oct 2017](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a325304d-1ab0-4c9c-84fb-68be98f3b2d9.pdf) |
| — | [PCS Certificate For Transfer/Transmission For The Quater Ended September,2017 14 Oct 2017](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2017/10/2eee51be-04d5-42e1-928b-e2f035ea83b4.pdf) |
| — | [Statement Of Investor Complaints For The Quater Ended June,2017 14 Oct 2017](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2017/10/a325304d-1ab0-4c9c-84fb-68be98f3b2d9.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2017 | [Concall - Oct 2017](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2017/10/b69d4250-e98a-4708-b264-4e92c0d9ea8e.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5d871498-77a1-482b-bb67-aa1563dd34e4.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/64d624f4-abde-48e7-b664-5e19fb4abbfd.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fe8a049f-7b61-4f7b-951e-12c24ed14f6a.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/75e154a2-0e6b-41be-b015-583b02f139dc.pdf) |
| Nov 2018 | [Concall - Nov 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/11/156b4106-7c1a-4dce-97b1-42f3e232d644.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/05d24616-20e1-4124-8abc-e5d35449894f.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/39a04e52-991b-49db-b02a-213451bbe4ea.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1b04ae8f-24b7-4e37-b852-32ef5119f5d8.pdf) |
| Mar 2017 | [Concall - Mar 2017](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2017/3/74d8b715-992a-4920-a6be-c0f11df667af.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7f191ad4-ed14-42f4-8579-719029bf2c1f.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b7127955-bd89-428e-84c5-149d9327e62d.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6743b848-aa4e-4e69-b72b-bc2334b39080.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/532326/74799532326.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/532326/71809532326.pdf) |
| from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/532326/66551532326_08_09_20.pdf) |
| from bse | [Financial Year 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/532326/5323260319.pdf) |
| from bse | [Financial Year 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/532326/5323260318.pdf) |
| from bse | [Financial Year 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/532326/5323260317.pdf) |
| from bse | [Financial Year 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport/532326/5323260316.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:58:26.191Z.